ERBB2 and breast cancer: Anti-4-1BB agonist monoclonal antibodies are under clinical investigation in combination with ICI in patients with locally advanced or metastatic TNBC (NCT02554812)(NCT03971409) and HER2-positive BC (NCT03414658).